CPC C07K 16/2869 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] | 24 Claims |
1. A method of reducing or lowering blood glucose levels in a human subject, the method comprising administering to the human subject a therapeutically effective amount of an antibody that specifically binds human glucagon receptor (GCGR; SEQ ID NO:223), wherein the antibody comprises: a heavy chain variable region (VH) comprising a VH complementarity determining region (CDR)1, a VH CDR2, and a VH CDR3 from the amino acid sequence of SEQ ID NO:25, and a light chain variable region (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the amino acid sequence of SEQ ID NO:26.
|